Ovid Therapeutics is a biopharmaceutical firm developing small-molecule drugs targeting neurological conditions centered on epilepsy and related seizure disorders. The company's pipeline includes OV329, a GABA-AT inhibitor in Phase 1 testing for drug-resistant epilepsy in adults and infants, and OV4071, an oral potassium-chloride cotransporter 2 activator also in Phase 1 trials for psychosis symptoms in Parkinson's disease, Lewy body dementia, and schizophrenia. The company maintains research partnerships with several pharmaceutical and academic institutions including AstraZeneca, Lundbeck, and Northwestern University.
1Y: 2.54 (+82.7%) · range 1.20–2.96
entry readiness 34 · NOT READY · exit proximity 0
Value area 2.26–2.71 · 41% of 120d volume overhead · moderate overhead
No source detections in the last 21 days.
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -3.18% | +3.53% | mature |
| 40d | -14.84% | +3.53% | mature |